Form 8-K Intra-Cellular Therapies For: Apr 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities
April 17, 2024 5:13 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More
